GigaGen Inc

GigaGen is a biopharmaceutical company developing novel antibody and T cell therapies derived from immune repertoires. GigaGen’s technology platform captures the genetic make-up of the entire human immune repertoire, capturing and genetically analyzing B and T cells at a rate of millions per hour, while simultaneously identifying their antigen and protein binders. Therapies derived from natural immune repertoires mimic the body's natural immune system - they can be more effective, can have fewer side effects, and can have faster development timelines than those developed from traditional methods. GigaGen has drug discovery projects with several pharmaceutical companies in addition to its own pipeline for development of the first recombinant intravenous immunoglobulin (IVIG) and immuno-oncology therapies.